Profiel
Alexandre Mouradian is the founder of eureKARE SA, eureKING SA. He is currently the Chairman of Spinoza Foundation, Director of Stellate Therapeutics SAS, Director of Omne Possibile, and Director of Meletios Therapeutics SAS. He completed his undergraduate degree at ESCP Europe Campus Paris.
Actieve functies van Alexandre Mouradian
| Bedrijven | Functie | Begin |
|---|---|---|
eureKARE SA
eureKARE SA BiotechnologyHealth Technology Operates as biotechnology company for microbiome and synthetic biology | Algemeen Directeur | - |
Meletios Therapeutics SAS
Meletios Therapeutics SAS BiotechnologyHealth Technology Operates as a biotechnology company that develops broad-spectrum therapeutic solutions | Directeur/Bestuurslid | - |
eureKING SA
eureKING SA Financial ConglomeratesFinance Operates as a special purpose acquisition company | Oprichter | - |
Spinoza Foundation | Voorzitter | - |
Omne Possibile | Directeur/Bestuurslid | - |
Stellate Therapeutics SAS
Stellate Therapeutics SAS BiotechnologyHealth Technology Develops innovative micro biome medicine for age related deceases | Directeur/Bestuurslid | - |
Opleiding van Alexandre Mouradian
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 7 |
|---|---|
ESCP Europe Campus Paris
ESCP Europe Campus Paris Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Stellate Therapeutics SAS
Stellate Therapeutics SAS BiotechnologyHealth Technology Develops innovative micro biome medicine for age related deceases | Health Technology |
Omne Possibile | |
eureKARE SA
eureKARE SA BiotechnologyHealth Technology Operates as biotechnology company for microbiome and synthetic biology | Health Technology |
Meletios Therapeutics SAS
Meletios Therapeutics SAS BiotechnologyHealth Technology Operates as a biotechnology company that develops broad-spectrum therapeutic solutions | Health Technology |
eureKING SA
eureKING SA Financial ConglomeratesFinance Operates as a special purpose acquisition company | Finance |
Spinoza Foundation |
















